Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
Type:
Grant
Filed:
April 15, 2022
Date of Patent:
January 30, 2024
Assignee:
Abacus Bioscience, Inc.
Inventors:
Edward A. Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
Abstract: Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.
Type:
Grant
Filed:
November 15, 2018
Date of Patent:
July 19, 2022
Assignees:
University of Washington, Abacus Bioscience, Inc.
Inventors:
Edward A. Clark, Che-Leung Law, Deborah Fuller, Michael Gale
Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
Type:
Grant
Filed:
November 22, 2016
Date of Patent:
May 10, 2022
Assignees:
University of Washington, Abacus Bioscience, Inc.
Inventors:
Edward Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak